Optimizing how people with Parkinson’s take their prescribed medication
By: Katherine Grosset*
Adherence to medication among people with Parkinson’s
It is widely known that compliance (also referred to as adherence) to prescribed medicines (taking a medication exactly to doctors’ recommendations) is sub-optimal across many different disease areas (1). However, it was thought that people with Parkinson’s (PwPs) would have high levels of compliance due to the highly symptomatic nature of the condition. We have conducted several studies of medication adherence in PwPs, using several different methods and examining several different factors that may affect adherence (2-6). Our findings support other compliance studies in PwPs that show sub-optimal adherence to Parkinson’s medications (2,4,7-10).
Simplifying treatment regimens in other diseases is known to improve adherence (1,11) and our findings have shown that once-daily Parkinson’s medications have better adherence rates than medications that are taken more frequently.2, 4 Involving PwPs in therapy decisions and ensuring that they know and are happy with their treatment regimen could also play a vital role in improving compliance intent (3,4).
Categories of non-compliance
In primary non-compliance, the patient does not seek to have the medication dispensed.
Intentional non-compliance includes the rejection of a diagnosis or advice or problems with prescription charges or collection. Medical opinion and patient interpretation may vary from the start of treatment, with patients balancing what they think is necessary for treatment against their concerns for adverse effects, tolerance and dependence (12). In Parkinson’s there can be concerns over improving current symptoms versus future symptom fluctuations. If treatment is recommended when the PwP considers it unnecessary, this can impair compliance.
Unintentional non-compliance may be due to forgetfulness that relates to mild symptoms, co-existent cognitive impairment (13,14) or depression (15,16).
This occurs later in the treatment pathway and has several sub-categories:
Adverse effects are a widely recognized reason for non-adherence and premature medication discontinuation in diseases such as depression(17) and Parkinson’s (18). Informing patients of potential adverse effects improves therapy continuation (19). Nausea and light-headedness are common when starting anti-Parkinson’s therapy, particularly with dopamine agonists; and although reduced by slow titration (a gradual dose increase) and/or taking domperidone, clinical trials in Parkinson’s show significant early discontinuation due to adverse effects (18,20-26).
Lack of efficacy also leads to the early discontinuation of treatment. PwPs often report a poor therapy response because they expect an improvement in tremor, but this only occurs in about half of the cases (27). Guidance about the expectations of therapy (improved movements and muscle tone) may reduce secondary non-compliance.
Irregular dosing: The aim of Parkinson’s medication is to mimic physiological dopamine, but peaks and troughs of erratic dopamine replacement – which can occur if medication is not taken on time – may contribute to the development of motor complications later in the disease (28). Our findings have shown that even if overall adherence to medication is good, they are often taken in an erratic and irregular way. It is important that patients know their medication regimen and are educated about the importance of taking their medication on time (4).
Overuse of medication: Medication overuse is well recognized, especially for those treatments with addictive properties. A subgroup of advanced PwPs take excess dopamine replacement therapy compulsively despite severe dyskinesia and psychiatric affects (29,30). Other PwPs overuse dopamine replacement therapy to a lesser degree, in the hope of returning to a ‘normal’ mobility state (31). However, our findings suggest that underuse of Parkinson’s medication is much more common than overuse (4).
The bottom line
Tablets do not work if they are not taken (32) – indeed we found that motor symptoms were significantly worse in patients with sub-optimal adherence versus those with satisfactory adherence (4). Complex treatment regimes are more difficult to comply with. Once-daily medications have significantly better adherence when compared to medications prescribed more frequently (2,4,10). Treatment tolerability, adverse effects and perceived efficacy must also be considered.
Proposed solutions for improving adherence
Concordance: A multitude of interventions to help patients take prescribed medication have been carried out in many disease areas. These include education programmes and physical cues/reminders that ‘advise’ patients on how to take their medication, but such programmes have shown marginal benefit to date (33).
PwPs are, however, much more likely to follow a treatment plan if they are involved in the decision-making process (3). Being informed about and understanding the advantages and disadvantages of the different options available to them help them feel assured that they are on the treatment course that is best suited to them.
Simplifying treatment regimes: It is generally more difficult to take medicines as prescribed if multiple treatments and frequent dosing schedules are required (1). Simplifying treatment regimens has proven beneficial in several disease areas (1,11).
In our work using electronic pill monitoring devices, we have found that the level of compliance deteriorated with increasing doses per day; in particular, it is very difficult to take medicines more than four doses per day on a regular basis (4) as there is no set cue to take the medication (such as breakfast, lunch, tea and bedtime). Once-daily medications were taken most consistently (4). Once-daily formulations are currently available for non-ergot dopamine agonists (prolonged release ropinirole and pramipexole, and rotigotine patch) and MAO-B inhibitors (selegiline and rasagiline).
It should be noted that for some once-daily medications, missing a tablet may have more of an effect on symptoms than missing one tablet of a more frequently dosed medication. However, this is medication-specific and dependent on the drug’s half-life (the time it takes for half the substance to decay).
Treating co-morbidities: Patients with depression are three times more likely to have poor adherence (34). This is especially important as depression commonly accompanies Parkinson’s (35) and has a major influence on quality of life (36,37). Cognitive impairment can also influence medicine-taking behavior (15,16) and, as a result, carers of PwPs play a vital role in ensuring medication is taken properly.
Parkinson’s treatment regimes are often complex, and adherence to medication is suboptimal. There are a number of solutions that can be implemented to help improve adherence, and involving PwPs and their carers in the therapy decision-making process – and ensuring they are happy with, and understand, their treatment regimen – can improve outcomes.
However, pharmacological approaches that make it easier for PwPs to take medicines to the best effect are key for successfully improving compliance. The current once-daily formulations, although often more expensive, should be optimised and the development of more effective long-lasting formulations for the treatment of later-disease stages would be greatly beneficial. It is important to bear in mind, though, that the main advantage of once-daily preparations is that they are once-daily. Their effectiveness and safety profiles are still comparable with other dosing preparations.
1. Claxton AJ, Cramer J, Pierce C. ‘A systematic review of the associations between dose regimens and medication compliance.’ Clin Ther 2001; 23(8): 1296-310.
2. Grosset KA, Bone I, Grosset DG. ‘Suboptimal medication adherence in Parkinson’s disease.’ Mov Disord 2005; 20(11): 1502-7.
3. Grosset KA, Grosset DG. ‘Patient-perceived involvement and satisfaction in Parkinson’s disease: effect on therapy decisions and quality of life.’ Mov Disord 2005; 20(5): 616-9.
4. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, et al. ‘Adherence to antiparkinson medication in a multicenter European study.’ Mov Disord 2009; 24(6): 826-32.
5. Grosset KA, Bone I, Reid JL, Grosset D. ‘Measuring therapy adherence in Parkinson’s disease: a comparison of methods.’ J Neurol Neurosurg Psychiatry 2006; 77(2): 249-51.
6. Grosset KA, Grosset DG. ‘Effect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trial.’ BMC Neurol 2007; 7:20.
7. Leopold NA, Polansky M, Hurka MR. ‘Drug adherence in Parkinson’s disease.’ Mov Disord 2004; 19(5): 513-7.
8. Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. ‘Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson’s disease.’ Mov Disord 2008; 23(3): 359-65.
9. Ng WT, Caslake R, Counsell CE. ‘Non-completion of changes to prescribed medications in people with Parkinson’s disease.’ Age Ageing 2007; 36(3): 333-6.
10. Tarrants ML, Denarie MF, Castelli-Haley J, Millard J, Zhang D. ‘Drug therapies for Parkinson’s disease: A database analysis of patient compliance and persistence.’ Am J Geriatr Pharmacother 2010; 8(4): 374-83
11. Richter A, Anton SE, Koch P, Dennett SL. ‘The impact of reducing dose frequency on health outcomes.’ Clin Ther 2003; 25(8): 2307-35; discussion 2306.
12. Horne R, Weinman J, Hankins M. ‘The Beliefs about Medicines Questionnaire (BMQ): the development and evaluation of a new method of assessing cognitive representations of medication.’ Psychol Health 1999; 14(1): 1-24.
13. Foltynie T, Brayne CE, Robbins TW, Barker RA. ‘The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study.’ Brain 2004; 127: 550-60.
14. Hobson P, Meara J. ‘Detected dementia and cognitive impairment in Parkinson’s Disease.’ Age Ageing 1999; 28(1): 39-43.
15. McDonald W, Richard I, DeLong M. ‘Prevalence, etiology, and treatment of depression in Parkinson’s disease.’ Biological Psychiatry 2003; 54(3): 363-375.
16. Chung TH, Deane KH, Ghazi-Noori S, Rickards H, Clarke CE. ‘Systematic review of antidepressant therapies in Parkinson’s disease.’ Parkinsonism Relat Disord 2003; 10(2): 59-65.
17. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, et al. ‘Discontinuing or switching selective serotonin-reuptake inhibitors.’ Ann Pharmacother 2002; 36(4): 578-84.
18. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, et al. ‘Ropinirole for the treatment of early Parkinson’s disease.’ The Ropinirole Study Group. Neurology 1997; 49(2): 393-9.
19. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, et al. ‘Discontinuation of use and switching of antidepressants: influence of patient-physician communication.’ JAMA 2002; 288(11): 1403-9.
20. Brooks DJ, Sagar H. ‘Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study.’ J Neurol Neurosurg Psychiatry 2003; 74(8): 1071-9.
21. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M. ‘The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease.’ Eur J Neurol 2003; 10(2): 137-46.
22. Parkinson Study Group. ‘Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial.’ JAMA 2000; 284(15): 1931-1938.
23. Koller WC, Hutton JT, Tolosa E, Capilldeo R. ‘Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study.’ Carbidopa/Levodopa Study Group. Neurology 1999; 53(5): 1012-9.
24. Linazasoro G, Grandas F, Martinez Martin P, Bravo JL. ‘Controlled release levodopa in Parkinson’s disease: influence of selection criteria and conversion recommendations in the clinical outcome of 450 patients.’ STAR Study Group. Clin Neuropharmacol 1999; 22(2): 74-9.
25. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. ‘Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa.’ The PKDS009 Collaborative Study Group. Neurology 1997; 48(2): 363-8.
26. Shannon KM, Bennett JP Jr, Friedman JH. ‘Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease.’ The Pramipexole Study Group. Neurology 1997; 49(3): 724-8.
27. Brooks DJ. ‘Diagnosis and management of atypical parkinsonian syndromes.’ J Neurol Neurosurg Psychiatry 2002; 72 2002; 72 Suppl 1: I10-I16.
28. Stocchi F, Vacca L, Ruggieri S, Olanow CW. ‘Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.’ Arch Neurol 2005; 62(6): 905-10.
29. Lawrence AD, Evans AH, Lees AJ. ‘Compulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry?’ Lancet Neurol 2003; 2(10): 595-604.
30. Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ. ‘Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies.’ J Neurol Neurosurg Psychiatry 2000; 68(4): 423-8.
31. Grosset KA, Reid JL, Grosset DG. ‘Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease.’ Mov Disord 2005; 20(11): 1397-404.
32. Urquhart J. ‘Role of patient compliance in clinical pharmacokinetics. A review of recent research.’ Clin Pharmacokinet 1994; 27(3): 202-15.
33. McDonald HP, Garg AX, Haynes RB. ‘Interventions to enhance patient adherence to medication prescriptions: scientific review.’ JAMA 2002; 288(22): 2868-79.
34. DiMatteo MR, Lepper HS, Croghan TW. ‘Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence.’ Arch Intern Med 2000; 160(14): 2101-7.
35. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. ‘Depression in Parkinson’s disease: clinical correlates and outcome.’ Parkinsonism Relat Disord 2003; 10(1): 23-8.
36. Global Parkinson’s Disease Survey Steering Committee. ‘Factors impacting on quality of life in Parkinson’s disease: results from an international survey.’ Mov Disord 2002; 17(1): 60-7.
37. Schrag A, Jahanshahi M, Quinn N. ‘What contributes to quality of life in patients with Parkinson’s disease?’ J Neurol Neurosurg Psychiatry 2000; 69(3): 308-12.
* Writing support provided by Teva and Lundbeck
Reprinted with Permission from the European Parkinson's Disease Association. To view the original article, visit their website.